SCHEMBL5623091

SCHEMBL5623091

CCNC(=O)Nc1ccc2ncc(-c3ccc(NC(=O)COCCOC)cc3)nc2n1

nearest known ligand 0.65

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 20/20 0.65
MAPK1 P28482 17/20 0.65
MAPK8 P45983 16/20 0.65
MAPK9 P45984 16/20 0.65
MAPK10 P53779 16/20 0.65
MAPK14 Q16539 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10328118 0.87 PIK3CA (0.67) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL5624480 0.86 MAPK1 (0.68) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL5623045 0.86 PIK3CA (0.66) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL5624937 0.86 PIK3CA (0.83) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL14506607 0.85 PIK3CA (0.72) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL4345920 0.84 PIK3CA (0.68) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL5623062 0.83 PIK3CA (0.78) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL4684872 0.83 PIK3CA (0.78) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL16674132 0.82 PIK3CA (0.71) PIK3CAMAPK1MAPK8MAPK9MAPK10
SCHEMBL5228918 0.82 PIK3CA (0.71) PIK3CAMAPK1MAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130157976-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES CLAUS ECKHARD (DE) 2013-06-20 US disclosed
US-20130157976-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES CLAUS ECKHARD (DE) 2013-06-20 US disclosed
US-20130157976-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES CLAUS ECKHARD (DE) 2013-06-20 US disclosed
US-20120252760-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ZENTARIS GMBH (DE) 2012-10-04 US disclosed
US-20120252760-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ZENTARIS GMBH (DE) 2012-10-04 US disclosed
US-20120252760-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ZENTARIS GMBH (DE) 2012-10-04 US disclosed
US-8217042-B2 Pyridopyrazines and their use as modulators of kinases ZENTARIS GMBH (DE) 2012-07-10 US disclosed
US-8217042-B2 Pyridopyrazines and their use as modulators of kinases ZENTARIS GMBH (DE) 2012-07-10 US disclosed
US-8217042-B2 Pyridopyrazines and their use as modulators of kinases ZENTARIS GMBH (DE) 2012-07-10 US disclosed
US-20070149484-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ZENTARIS GMBH (DE) 2007-06-28 US disclosed
US-20070149484-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ZENTARIS GMBH (DE) 2007-06-28 US disclosed
US-20070149484-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ZENTARIS GMBH (DE) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149484-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES MAP4K2, MAP3K15, MAP3K5 PIK3CA 279/4885MAPK1 47/4885MAPK8 191/4885
US-20120252760-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES MAP4K2, MAP3K15, MAP3K5 PIK3CA 279/4885MAPK1 47/4885MAPK8 191/4885
US-20130157976-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES MAP4K2, MAP3K15, MAP3K5 PIK3CA 279/4885MAPK1 47/4885MAPK8 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.